DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Felip E, Orlov S, Park K et al.
ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).
J Clin Oncol 2015; (suppl): abstr 8060
33
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.